Atlas Trials

CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome)

Clinical trial NCT03566043 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03566043
Sponsor
REGENXBIO Inc.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Mucopolysaccharidosis Type II (MPS II)
Start date
2018-09-27
Primary completion
2023-11-27
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.